S. Wilhelm

发表

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

J. Llovet, S. Wilhelm, Lila Adnane, 2008, Molecular Cancer Therapeutics.

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.

S. Wilhelm, J. Gollob, C. Carter, 2006, Seminars in oncology.

Discovery of a novel Raf kinase inhibitor.

G. Bollag, J. Lyons, S. Wilhelm, 2001, Endocrine-related cancer.

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

D. Auclair, P. Vincent, G. Bollag, 2004, Cancer Research.

Antitumor activity of sorafenib in FLT3-driven leukemic cells

D. Auclair, S. Wilhelm, M. Lynch, 2007, Leukemia.

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.

S. Wilhelm, Lila Adnane, I. Taylor, 2006, Methods in enzymology.

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

S. Wilhelm, M. Lynch, B. Schwartz, 2007, Nature Reviews Drug Discovery.

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

D. Zopf, K. Thierauch, S. Wilhelm, 2011, International journal of cancer.

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

S. Wilhelm, M. Lynch, B. Schwartz, 2006, Nature Reviews Drug Discovery.

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

S. Wilhelm, M. Lynch, Christopher A. Carter, 2006, Cancer research.

Hepatocellular Carcinoma Model PLC / PRF / 5 Tumor Angiogenesis , and Induces Tumor Cell Apoptosis in Sorafenib Blocks the RAF / MEK / ERK Pathway , Inhibits

S. Wilhelm, M. Lynch, Christopher A. Carter, 2006 .

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib

J. Thiery, S. Venkatesh, B. Goh, 2015, Journal of Translational Medicine.

SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer.

L. Perkins, I. Enyedy, Antonella Bacchiocchi, 2007, Bioorganic & medicinal chemistry letters.

Receptor Tyrosine Kinases Involved in Tumor Progression Activity and Targets the RAF/MEK/ERK Pathway and BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor

D. Auclair, P. Vincent, G. Bollag, 2004 .

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

M. Kattan, C. Parker, S. Nilsson, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.

J. S. Johnson, T. Turner, S. Wilhelm, 2000, Bioorganic & medicinal chemistry letters.

BAY 43-9006 inhibition of oncogenic RET mutants.

M. Santoro, Suresh Anaganti, G. Troncone, 2006, Journal of the National Cancer Institute.

Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006)

Hong Shi, J. Elting, S. Wilhelm, 2006 .

2013 Analysis of biomarkers in circulating tumor DNA from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC): Correlation with clinical outcome

M. Teufel, Tae Won Kim, S. Wilhelm, 2015 .

Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.

J. Guinney, M. Teufel, P. Wirapati, 2015 .

Baseline phosphorylated ERK levels in renal cell carcinoma patients from a phase II study of BAY 43–9006.

S. Wilhelm, D. Wilkie, Angela McNabola, 2004 .

Abstract B4: Regorafenib: a new oral multikinase inhibitor of angiogenic, stromal and oncogenic (receptor tyrosine) kinases with potent preclinical antitumor activity

J. Hornberg, D. Zopf, K. Thierauch, 2009 .

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

M. Kattan, C. Parker, S. Nilsson, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract 1666: Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolites

D. Zopf, K. Thierauch, S. Wilhelm, 2010 .

p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.

J. S. Johnson, S. Wilhelm, W. Scott, 2001, Bioorganic & Medicinal Chemistry Letters.

1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.

J. S. Johnson, T. Turner, S. Wilhelm, 2000, Bioorganic & medicinal chemistry letters.

BAY 43-9006: preclinical data.

S. Wilhelm, D. Chien, 2002, Current pharmaceutical design.

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

A. Haegebarth, S. Wilhelm, K. Ziegelbauer, 2013, Molecular Cancer Therapeutics.

Small Molecule Therapeutics BAY 80-6946 Is a Highly Selective Intravenous PI 3 K Inhibitor with Potent p 110 a and p 110 d Activities in Tumor Cell Lines and Xenograft Models

A. Haegebarth, S. Wilhelm, K. Ziegelbauer, 2013 .

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

A. Rosenthal, Robert Schmieder, D. Zopf, 2014, International journal of cancer.

BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma

M. Santoro, G. Troncone, V. De Falco, 2006, Clinical Cancer Research.

Abstract 2337: Regorafenib (BAY 73-4506): Anti-metastatic activity in a mouse model of colorectal cancer

Robert Schmieder, D. Zopf, S. Wilhelm, 2012 .

Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor β Gatekeeper Mutants

M. Santoro, Suresh Anaganti, S. Wilhelm, 2007, Clinical Cancer Research.

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

S. Wilhelm, M. Lynch, Chen Chen, 2007, Cancer Chemotherapy and Pharmacology.

G. Bollag, J. Lyons, S. Wilhelm, 2001 .

Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor.

S. Wilhelm, W. Scott, J. Pirro, 2002, Bioorganic & medicinal chemistry letters.

Discovery of a new class of p38 kinase inhibitors.

J. S. Johnson, S. Wilhelm, W. Scott, 2000, Bioorganic & medicinal chemistry letters.

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma

K. Podar, S. Wilhelm, M. Raab, 2018, Annals of Hematology.

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

I. Fichtner, D. Zopf, K. Thierauch, 2016, Cancer medicine.

865 Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA trial

C. Parker, O. Sartor, S. Wilhelm, 2014 .

Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes.

C. Parker, S. Wilhelm, M. Shan, 2013 .

A Potent Nonpeptidic Matrix Metalloproteinase Inhibitor

S. Wilhelm, B. Hibner, R. Humphrey, 2001 .

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib

J. Thiery, S. Venkatesh, B. Goh, 2015, Journal of Translational Medicine.

Recent advances in the research and development of RAF kinase inhibitors.

S. Wilhelm, Lila Adnane, J. Dumas, 2006, Current topics in medicinal chemistry.

Abstract 4509: BAY 87-2243 targets hypoxia-induced activation and stabilization of HIF-1α: A novel approach to overcome resistance mechanisms in cancer therapy

K. Thierauch, S. Wilhelm, K. Ziegelbauer, 2011 .

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

D. Auclair, P. Vincent, G. Bollag, 2004, Cancer Research.